Researchers working for biotech giant Aventis Behring (AB) are due to unveil important developments of a new, highly sensitive test to detect the presence of prions, at the 43rd annual meeting of the American Society of Hematology today [Tuesday].  Delegates at the meeting, in Orlando, Florida, will hear about the effectiveness of the new rapid test, Conformation Dependent Immunoassay (CDI), for detecting small amounts of prions in otherwise normal plasma donations.